Trademark Overview
On Wednesday, December 27, 2023, a trademark application was filed for RENBIOLOGICS with the United States Patent and Trademark Office. The USPTO has given the RENBIOLOGICS trademark a serial number of 79395221. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, February 24, 2025. This trademark is owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. The RENBIOLOGICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Medicines for human purposes; biological preparations for medical purposes; preparations of microorganisms for medical or veterinary use; biological tissue cultures for medical purposes; colostral antibodies for medical purposes; vaccines; living cells for medical purposes; biochemical medicines; pharmaceutical preparations; pharmaceutical substances; medical preparations for treating diseases and disorders related to the immune system; pharmaceutical preparations for the prevention and treatment of cancer; diagnostic preparations for medical purposes; dietetic substances adapted for medical use; medicines for veterinary purposes.
Protein [raw material]; radioactive elements for scientific purposes; preparations of trace elements for plants; biochemical preparations for scientific purposes; biological preparations, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; biological tissue cultures other than for medical or veterinary purpose; bacteriological preparations other than for medical and veterinary use; preparations of microorganisms, other than for medical and veterinary use; proteins for the food industry.
Technological research; biochemical research and analysis; drug development; pharmaceutical product evaluation; clinical trials; research and development services in the field of antibodies; biological research; research in the field of gene editing technology; research in the field of cell engineering technology; culturing of cells for scientific research purposes; development of pharmaceutical preparations and pharmaceuticals; biomedical research.
